Sitagliptin

Generic Name: Sitagliptin

Brand Names: Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₅F_₆N_₅O

CAS Number: 486460-32-6

Unique Ingredient Identifier: QFP0P1DV7Z

Background: Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on Oct...

Indication: Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.

It is also used in combination with metformin or ertugliflozin.

Associated Conditions: Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

Phase 4

Completed

Conditions: Hyperglycemia

Interventions: Drug: Placebo
Drug: Sitagliptin
Drug: Supplemental insulin (insulin lispro)
Drug: Supplemental insulin (insulin aspart)
Drug: Long acting basal insulin (insulin detemir)
Drug: Long acting basal insulin (insulin glargine)

First Posted Date: 2016-04-18

Last Posted Date: 2018-06-27

Lead Sponsor: Emory University

Target Recruit Count: 80

Registration Number: NCT02741687

Locations: 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States

Randomized Sitagliptin Withdrawal Study (MK-0431-845)

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo to sitagliptin
Drug: Sitagliptin
Drug: Metformin
Drug: Metformin XR
Drug: Insulin glargine

First Posted Date: 2016-04-14

Last Posted Date: 2019-02-25

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 746

Registration Number: NCT02738879

Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Evogliptin
Drug: Sitagliptin
Drug: Placebo Sitagliptin
Drug: Placebo Evogliptin

First Posted Date: 2016-02-23

Last Posted Date: 2018-08-14

Lead Sponsor: Eurofarma Laboratorios S.A.

Target Recruit Count: 146

Registration Number: NCT02689362

Locations: 🇧🇷
Clinica de Endocrinologia e Metabologia LTDA, São Paulo, Brazil
🇧🇷
CCBR Brasil Centro de Pesquisas e Analises Clinicas Ltda, Rio de Janeiro, Brazil
🇧🇷
CPCLIN - Centro de Pesquisas Clinicas LTDA, São Paulo, Brazil

and more 7 locations

Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Completed

Conditions: Graft vs Host Disease
Hematopoietic Stem Cell Transplantation

Interventions: Drug: Sitagliptin

First Posted Date: 2016-02-17

Last Posted Date: 2021-01-22

Lead Sponsor: Sherif S. Farag

Target Recruit Count: 37

Registration Number: NCT02683525

Locations: 🇺🇸
Indiana University Health Hospital, Indianapolis, Indiana, United States
🇺🇸
Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

Accelerated Wound Healing in Diabetic Ulcers by Sitagliptin

Phase 3

Withdrawn

Conditions: Diabetic Foot

Interventions: Drug: Placebo
Drug: Sitagliptin

First Posted Date: 2016-02-05

Last Posted Date: 2016-09-15

Lead Sponsor: Wolfgang-Michael Franz

Registration Number: NCT02675335

Effect of Sitagliptin on Progression of Coronary Intermediate Lesion

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus
Atherosclerosis

Interventions: Drug: Placebo
Drug: Sitagliptin

First Posted Date: 2016-01-14

Last Posted Date: 2018-01-25

Lead Sponsor: Li Bo

Target Recruit Count: 120

Registration Number: NCT02655757

Locations: 🇨🇳
The General Hospital of PLA, Beijing, Beijing, China

A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection

Phase 1

Completed

Conditions: Hepato Carcinoma

Interventions: Drug: Sitagliptin

First Posted Date: 2016-01-08

Last Posted Date: 2018-10-18

Lead Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

Target Recruit Count: 14

Registration Number: NCT02650427

Locations: 🇫🇷
Pitié-Salpêtrière Hospital, Paris, France

Effect of DPP4 Inhibition on Vasoconstriction

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Sitagliptin
Drug: Placebo
Drug: Valsartan 160mg
Drug: Neuropeptide Y
Drug: Enalaprilat

First Posted Date: 2015-12-24

Last Posted Date: 2018-08-27

Lead Sponsor: Vanderbilt University

Target Recruit Count: 18

Registration Number: NCT02639637

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

Not Applicable

Completed

Conditions: Type2 Diabetes Mellitus

Interventions: Drug: DS-8500a
Drug: Sitagliptin
Drug: placebo

First Posted Date: 2015-12-11

Last Posted Date: 2019-02-12

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 368

Registration Number: NCT02628392

Locations: 🇯🇵
Heishinkai Medical Group Incorporated OCROM Clinic, Suita-shi, Osaka, Japan

Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: NPH insulin
Drug: sitagliptin

First Posted Date: 2015-11-18

Last Posted Date: 2015-11-18

Lead Sponsor: University of Sao Paulo General Hospital

Target Recruit Count: 40

Registration Number: NCT02607410

Locations: 🇧🇷
University of Sao Paulo General Hospital, Sao Paulo, Brazil

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy